• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Value analysis of CD69 combined with EGR1 in the diagnosis of coronary heart disease
【2h】

Value analysis of CD69 combined with EGR1 in the diagnosis of coronary heart disease

机译：CD69联合EGR1在冠心病诊断中的价值分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Expression and clinical significance of CD69 and early growth response (EGR1) in plasma of patients with coronary heart disease (CHD) were investigated. A total of 194 patients with CHD and 130 healthy subjects, respectively, were selected as CHD and control group, clinical data were collected and coronary angiography was performed. RT-qPCR was used to detect the expression of EGR1. Flow cytometry was used to detect the expression level of CD69 and the receiver operating characteristic curve was used to analyze the values of relative expression of CD69 and EGR1. The relative expression of CD69 in plasma of patients with CHD was higher than that in control group, while the relative expression of EGR1 was lower than that in control group. The relative expression of EGR1 in plasma of patients with CHD was negatively correlated with lipoprotein a [Lp(a)] and high sensitive C-reactive protein (hs-CRP) (r=−0.394 and −0.524, P<0.05), and the relative expression of CD69 in peripheral blood was positively correlated with [Lp(a)] and hs-CRP (r=0.352 and 0.402, P<0.05). The area under curve (AUC) of the relative expression of CD69 in peripheral blood of patients with CHD in evaluating the course of the disease of patients was 0.889 (95% CI: 0.822–0.958). The AUC of the relative expression of EGR1 in plasma in evaluating the course of the disease of patients was 0.933 (95% CI: 0.867–0.978). By the combined detection of CD69 and EGR1, it was found that the AUC was 0.954 (95% CI: 0.887–0.982). The expression level of EGR1 in plasma of patients with CHD decreased, while the expression level of CD69 increased, and both of them were related to the severity of the disease of patients, which could be used as an indicator to evaluate the progression of the patients' conditions.
机译：研究了冠心病（CHD）患者血浆中CD69和早期生长反应（EGR1）的表达及其临床意义。分别选择194例冠心病和130例健康人作为冠心病和对照组，收集临床资料并进行冠状动脉造影。 RT-qPCR用于检测EGR1的表达。用流式细胞术检测CD69的表达水平，用受体工作特征曲线分析CD69和EGR1的相对表达值。冠心病患者血浆CD69的相对表达高于对照组，而EGR1的相对表达低于对照组。冠心病患者血浆中EGR1的相对表达与脂蛋白a [Lp（a）]和高敏C反应蛋白（hs-CRP）呈负相关（r = -0.394和-0.524，P <0.05），并且CD69在外周血中的相对表达与[Lp（a）]和hs-CRP呈正相关（r = 0.352和0.402，P <0.05）。在评估患者病程时，冠心病患者外周血CD69相对表达的曲线下面积（AUC）为0.889（95％CI：0.822-0.958）。在评估患者病程中，血浆EGR1相对表达的AUC为0.933（95％CI：0.867-0.978）。通过对CD69和EGR1的联合检测，发现AUC为0.954（95％CI：0.887-0.982）。冠心病患者血浆中EGR1的表达水平降低，而CD69的表达水平升高，且两者均与患者疾病的严重程度有关，可作为评价患者病情进展的指标' 条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号